Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Items 701–800 of 1,002
Surviving Sepsis Campaign: Research Opportunities for Infection and Blood Purification Therapies
Martín‐Loeches, I., Nunnally, M., Hellman, J., Lat, I., Martin, G. S., Jog, S., Kesecioğlu, J., Backer, D. D., & Coopersmith, C. M. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000511 · Cited by 23
“Work has been done in this field with studies of adjusted aminoglycoside daily dosing given their pharmacokinetics characteristics, but there is greater opportunity for expanding adjusted dosing to other antimicrobials (49, 50).”
BackgroundHigh versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis
Meng, L., Fang, Y., Chen, Y., Zhu, H., & Long, R. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000182 · Cited by 20
Gunther, M., Saxinger, L. M., Gray, M. H., & LeGatt, D. F. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r566 · Cited by 20
DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates
Tasa, T., Metsvaht, T., Kalamees, R., Vilo, J., & Lutsar, I. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000456 · Cited by 20
Optimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles
Hoo, G. S. R., Liew, Y. X., & Kwa, A. L. (2017) · Indian Journal of Medical Microbiology · doi:10.4103/ijmm.ijmm_17_278 · Cited by 25
“aureus, a consensus paper in 2009 recommends targeting serum trough concentrations of 15–20 mg/L to increase the probability of attaining the PK/PD target of AUC/MIC ≥400.[45] In patients with normal renal function, this target is not achievable with conventional dosing methods if the MIC is ≥2 mg/L, and alternative c…”
BackgroundInfluentialLi, Z., Liu, S., Chen, H., Zhang, X., Ling, Y., Zhang, N., & Tieying, H. (2020) · Acta Clinica Belgica · doi:10.1080/17843286.2020.1797343 · Cited by 20
Vancomycin Dosing in Healthy-Weight, Overweight, and Obese Pediatric Patients
Eiland, L. S., & Sonawane, K. (2014) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-19.3.182 · Cited by 19
Dong, M., Wang, J., Wu, Y., Chen, B., Yu, M., & Wen, A. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.06.025 · Cited by 19
Defining Antibiotic Dosing in Lung Infections
Jamal, J., Abdul-Aziz, M. H., Lipman, J., & Roberts, J. A. (2013) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e31828fc646 · Cited by 19
“Maintaining a constant plasma concentration (eg, 20 mg/L) to enhance drug concentrations in the lung compartment,(19,32) supports the use of therapeutic drug monitoring (TDM) to guide dosing with vancomycin.(43) The use of vancomycin to treat less susceptible pathogens in lung infection could be considered unreliable…”
BackgroundMacVane, S. H., So, W., Nicolau, D. P., & Kuti, J. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03742-14 · Cited by 19
“Based on this report and others in bacteremia, a consensus guideline from the IDSA, Society of Infectious Diseases Pharmacists, and American Society of Health-Systems Pharmacists suggests that alternative treatment options should be carefully considered when the vancomycin MIC exceeds 1 g/ml (27).”
BackgroundSingh, N. B., Yim, J., Jahanbakhsh, S., Sakoulas, G., & Rybak, M. J. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.03.020 · Cited by 20
Self-citationGustinetti, G., Cangemi, G., Bandettini, R., & Castagnola, E. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1377909 · Cited by 19
Dilworth, T. J., Casapao, A. M., Ibrahim, O. M., Jacobs, D. M., Bowers, D. R., Beyda, N. D., & Mercier, R.-C. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02211-18 · Cited by 19
Significant Publications on Infectious Diseases Pharmacotherapy in 2017
Skoglund, E. W., Dotson, K. M., Dempsey, C. J., Su, C. P., Foolad, F., Janak, C. E., Sofjan, A. K., & Phe, K. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018792797 · Cited by 20
Valero, Y. C. G., Roberts, J. A., Lipman, J., Fourie, C., Starr, T., Wallis, S. C., & Parker, S. L. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.03.018 · Cited by 19
Liu, T., Pang, H.-M., Li, J., Wei, W., Qin, X., Guo, Q., Lu, H., Cheng, D.-H., & Jiang, W. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13071 · Cited by 19
Zhang, T., Cheng, H., Pan, Z., Mi, J., Dong, Y., Zhang, Y., Sun, D., Du, Q., Cheng, X., & Dong, Y. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13303 · Cited by 19
Does oral vancomycin use necessitate therapeutic drug monitoring?
Cimolai, N. (2019) · Infection · doi:10.1007/s15010-019-01374-7 · Cited by 19
Badri, S., Soltani, R., Sayadi, M., Khorvash, F., Meidani, M., & Taheri, S. (2020) · Archives of Iranian Medicine · doi:10.34172/aim.2020.33 · Cited by 19
“The inclusion criteria included (1) age > 18 years; (2) receiving vancomycin for at least 10 days; (3) creatinine clearance (CrCl) > 60 mL/min; (4) no proteinuria and/or hematuria; (5) no renal disorder including glomerulonephritis, polycystic kidney disease, and renal artery stenosis; (6) no history of AKI; (7) no se…”
BackgroundA survey of therapeutic drug monitoring in a teaching hospital
Almohammde, S., Alhodian, H., Almofareh, S., Alshehri, S. O., Almasri, D. M., & Ghoneim, R. H. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.11.002 · Cited by 19
Continued professional development: A comparison of online vs. in-person workshops
Gallegos, P. J., Mistry, B., Freshwater, D., & Mullen, C. L. (2021) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2021.03.019 · Cited by 19
Poston-Blahnik, A., & Moenster, R. P. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab094 · Cited by 19
Cheong, J. Y., Makmor‐Bakry, M., Lau, C. L., & Rahman, R. A. (2012) · South African Medical Journal · doi:10.7196/samj.5343 · Cited by 19
Luther, M. K., & LaPlante, K. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01604-15 · Cited by 19
Experience with Continuous Infusion Vancomycin Dosing in a Large Pediatric Hospital
Hurst, A. L., Baumgartner, C., MacBrayne, C. E., & Child, J. (2018) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piy032 · Cited by 19
Assessment of initial vancomycin dosing in neonates
Dersch‐Mills, D., Bengry, T., Akierman, A., Alshaikh, B. N., & Yusuf, K. (2014) · Paediatrics & Child Health · doi:10.1093/pch/19.6.e30 · Cited by 19
Vancomycin: Over 50 Years Later and Still a Work in Progress
Rybak, M. J., Rotschafer, J. C., & Rodvold, K. A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1382 · Cited by 19
Self-citationQuality, origins and limitations of common therapeutic drug reference intervals
McCudden, C. R. (2018) · Diagnosis · doi:10.1515/dx-2018-0001 · Cited by 20
Duan, L., Zhang, J., Chen, Z., Gou, Q., Xiong, Q., Yuan, Y., Jing, H., Zhu, J., Ni, L., Zheng, Y., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s325286 · Cited by 19
Risk Scoring System for Vancomycin-Associated Acute Kidney Injury
Kim, J. Y., Kim, K. Y., Yee, J., & Gwak, H. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.815188 · Cited by 20
Miyai, T., Imai, S., Yoshimura, E., Kashiwagi, H., Sato, Y., Ueno, H., Takekuma, Y., & Sugawara, M. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00305 · Cited by 19
Prevention and management of hearing loss in patients receiving ototoxic medications
Lindeborg, M. M., Jung, D. H., Chan, D. K., & Mitnick, C. D. (2022) · Bulletin of the World Health Organization · doi:10.2471/blt.21.286823 · Cited by 18
“macrolides include old age, kidney dysfunction and co-administration with other ototoxic agents.(22) Given the relatively low incidence of ototoxicity and weak evidence that they are”
BackgroundPharmacotherapy for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia
Segarra‐Newnham, M., & Church, T. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r370 · Cited by 20
Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis
Alves, G. C. D. S., da Silva, S. D., Frade, V. P., Rodrigues, D., Baldoni, A. O., de Castro, W. V., & Sanches, C. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2306-3 · Cited by 18
Ishii, H., Hirai, K., Sugiyama, K., Nakatani, E., Kimura, M., & Itoh, K. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000562 · Cited by 18
Sohn, Y., Rim, J. H., Cho, Y., Hyun, J. H., Baek, Y. J., Kim, M., Kim, J. H., Seong, H., Ahn, J. Y., Lee, S., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06809-x · Cited by 18
“Because it has adverse effects such as nephrotoxicity, studies have examined the pharmacokinetics of vancomycin to minimize its toxicity and maximize its therapeutic effect [6].”
BackgroundCompartmentalized Polymeric Nanoparticles Deliver Vancomycin in a pH-Responsive Manner
Ural, M. S., Menéndez-Miranda, M., Salzano, G., Mathurin, J., Aybeke, E., Deniset‐Besseau, A., Dazzi, A., Porcino, M., Martineau, C., & Gref, R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13121992 · Cited by 18
Is vancomycin redundant for serious staphylococcal infection?
Gould, I. M. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.005 · Cited by 19
Evaluation of glycopeptide use in nine French hospitals
Alfandari, S., Levent, T., Descamps, D., Hendricx, S., Bonenfant, C., Taines, V., Cattoen, C., Arimane, O., & Grandbastien, B. (2009) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2009.10.019 · Cited by 18
Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia
Hochart, C., Berthon, C., Corm, S., Gay, J., Cliquennois, M., Tricot, S., & Alfandari, S. (2011) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2011.09.014 · Cited by 18
“Furthermore, the inappropriate use of vancomycin has been suspected as a possible explanation for the selection of vancomycin resistant enterococci and/or vancomycin intermediate staphylococci [3].”
BackgroundInfluentialVancomycin Pharmacokinetics and Pharmacodynamics during Short Daily Hemodialysis
Decker, B. S., Kays, M. B., Chambers, M., Kraus, M. A., Moe, S. M., & Sowinski, K. M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03450410 · Cited by 19
Choosing Optimal Antimicrobial Therapies
Lynch, T. J. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.08.006 · Cited by 22
Therapeutic Drugs and Their Management
Snozek, C. L. H., McMillin, G. A., & Moyer, T. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6164-9.00034-2 · Cited by 19
Phillips, C. J., McKinnon, R. A., Woodman, R. J., & Gordon, D. (2017) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2017.09.010 · Cited by 19
“The guideline largely reflected the North American consensus recommendations adapted with Australian Therapeutic Guidelines content on vancomycin [29-30].”
Truong, J. Q., Smith, S. R., Veillette, J. J., & Forland, S. C. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1273 · Cited by 18
Vancomycin-Associated Acute Kidney Injury in Critically Ill Adolescent and Young Adult Patients
Hays, W. B., & Tillman, E. M. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019829652 · Cited by 18
“5 mg/dL or 50% from baseline for 2 consecutive days.(1) Upon identification of AKI incidence rate, patients were compared in 2 separate arms: (1) patients who developed AKI and (2) patients who did not develop AKI.”
BackgroundMethodFalsely Elevated Vancomycin Concentrations in a Patient Not Receiving Vancomycin
Tsoi, V., Bhayana, V., Bombassaro, A. M., Tirona, R. G., & Kittanakom, S. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2279 · Cited by 18
“Therapeutic drug monitoring (TDM) of vancomycin trough concentrations is recommended by the Infectious Diseases Society of America to minimize the risks of therapeutic failure and/or nephrotoxicity.(1) Commercially available immunoassays are commonly used to determine serum vancomycin concentrations for TDM.”
MethodTunkel, A. R., van de Beek, D., & Scheld, W. M. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00089-8 · Cited by 27
Newer developments in the treatment of Gram-positive infections
Koomanachai, P., Crandon, J. L., & Nicolau, D. P. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903357491 · Cited by 18
Dawoud, T. H., Khan, N., Afzal, U., Varghese, N. V., Rahmani, A., & Sa’da, O. A. (2020) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2019-002181 · Cited by 17
Raval, Y. S., Fleming, D. F., Mohamed, A. H., Karau, M. J., Mandrekar, J. N., Schuetz, A. N., Greenwood‐Quaintance, K. E., Beyenal, H., & Patel, R. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300059 · Cited by 18
Oda, K., Saito, H., & Jono, H. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108433 · Cited by 19
Blechman, S. E., & Wright, E. S. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012422 · Cited by 24
Therapeutic Drug Monitoring (TDM)
Routledge, P. A., & Hutchings, A. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-08-097037-0.00076-2 · Cited by 17
Nephrotoxicity Comparison of Two Commercially Available Generic Vancomycin Products
Sutton, J. D., Mynatt, R. P., Kaye, K. S., Murray, K. P., Rybak, M. J., & Pogue, J. M. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00388-15 · Cited by 17
“Three nephrotoxicity definitions were used: the 2009 consensus vancomycin guideline (1) and Acute Kidney Injury Network (AKIN) (7, 8) and RIFLE (risk, injury, failure, loss, and end-stage renal disease) criteria (7, 8) (Table 1).”
BackgroundMethodInfluentialSelf-citationRisk of Vancomycin-induced Nephrotoxicity in the Population With Chronic Kidney Disease
Panwar, B., Johnson, V. A., Patel, M., & Balkovetz, D. F. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318268023d · Cited by 17
“10 mg/mL to avoid the development of resistance and up to 15 to 20 mg/mL in severe S aureus infections.(20) All currently available nomograms for dosing of vancomycin in the population with CKD have not been adjusted for attaining higher trough levels.”
BackgroundTherapeutic Drug Monitoring–the Appropriate Use of Drug Level Measurement in the Care of the Neonate
Young, T. E. (2012) · Clinics in Perinatology · doi:10.1016/j.clp.2011.12.009 · Cited by 21
Rege, S., Mohr, J., Lamp, K. C., Yoon, M., & Lindfield, K. C. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.12.008 · Cited by 17
Caffrey, A. R., Quilliam, B. J., & LaPlante, K. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00200-10 · Cited by 17
“Additionally, we expect the average MIC of our national VA cohort to correspond with the national average MIC of 1 mg/liter (9, 27, 34).”
Ishikawa, M., Yamazaki, S., Suzuki, T., Uchida, M., Iwadate, Y., & Ishii, I. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.10.013 · Cited by 17
Diagnosis, treatment and prevention of infective endocarditis: Turkish consensus report-2019*
Yavuz, S. Ş., Akar, A. R., Aydoğdu, S., Deniz, D. B., Demir, H., Hazırolan, T., Ozatik, M. A., Özer, N., Sargın, M., Topçuoğlu, N., et al. (2020) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2020.89689 · Cited by 25
Allawati, H., Dallas, L., Nair, S., Palmer, J., Thaikandy, S., & Hutchison, C. A. (2020) · Toxins · doi:10.3390/toxins12050317 · Cited by 17
“Trough vancomycin serum concentrations maintained between 10–15 mg/L are recommended for mild infections and 15–20 mg/L in severe infections [24].”
BackgroundMethodRivera, A., Sánchez, A., Luque, S., Mur, I., Puig, L., Crusi, X., Rodríguez, J. C. G., Sorlí, L., Osuna, A. G., Horcajada, J. P., et al. (2020) · Antibiotics · doi:10.3390/antibiotics10010018 · Cited by 17
“Total measured concentrations of cefazolin, cefuroxime and vancomycin were adjusted to free concentrations, assuming protein binding of 80%, 40% and 50%, respectively [20,21].”
BackgroundScheetz, M. H., Pais, G. M., Lodise, T. P., Tong, S. Y. C., Davis, J. S., O’Donnell, J. N., Liu, J., Neely, M. N., Prozialeck, W. C., Lamar, P. C., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01060-21 · Cited by 17
Doddangoudar, V. C., Boost, M. V., Tsang, D. N. C., & O'Donoghue, M. M. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03463.x · Cited by 17
“MRSA-infected patients failing to respond to vancomycin are often prescribed a higher dose to increase the trough value of the drug [14,15].”
BackgroundVANCOMYCIN: THE TALE OF THE VANQUISHER AND THE PYRRHIC VICTORY
Vriese, A. S. D., & Vandecasteele, S. J. (2014) · Peritoneal Dialysis International · doi:10.3747/pdi.2014.00001 · Cited by 19
“Theoretically, when using vancomycin, the pharmacologic target that assures microbiologic effectiveness is a ratio of more than 400 for the area under the 24-hour concentration curve divided by the MIC (4,6).”
BackgroundInfluentialColeman, L. K., & Wilson, A. S. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190014568381 · Cited by 17
“Vancomycin trough concentrations are recommended to guide dosing decisions and predict efficacy.(1) Improperly timed vancomycin trough concentration collection can lead to inappropriate clinical decision making.”
BackgroundMethodInfluentialTakahashi, Y., Takesue, Y., Takubo, S., Ishihara, M., Nakajima, K., Tsuchida, T., Ikeuchi, H., & Uchino, M. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0551-7 · Cited by 17
“state conditions [4, 7].”
BackgroundDeCarolis, D. D., Thorson, J. G., Marraffa, R. A., Clairmont, M. A., & Kuskowski, M. A. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000065 · Cited by 17
“General recommendations call for measurement of a steady-state trough serum vancomycin concentration to ensure that the dose provides the recommended target concentrations.(16) However, such an assessment of proper dose is often delayed for several days because of the time required to achieve vancomycin steady-state c…”
BackgroundInfluentialVancomycin and the Risk of AKI: Now Clearer than Mississippi Mud
Nolin, T. D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11011016 · Cited by 17
“aureus infections to achieve the targeted area under the concentrationtime curve-to-minimum inhibitory concentration ratio of $400 (12).”
BackgroundUse of Daptomycin to Manage Severe MRSA Infections in Humans
Fiore, M., Alfieri, A., Fiore, D., Iuliano, P., Spatola, F. G., Limone, A., Pezone, I., & Leone, S. (2025) · Antibiotics · doi:10.3390/antibiotics14060617 · Cited by 18
“Nevertheless, significant pharmacokinetic and pharmacodynamic limitations associated with these agents—including poor tissue penetration, slow bactericidal activity, and high protein binding—have progressively undermined their clinical efficacy [4].”
Cai, Y., Zhou, L., Wang, H., Zhang, L., Wang, J., & Zhang, K. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12770 · Cited by 16
Garms, D. S. D. S., Eid, K. Z. C., Burdmann, E. A., Marçal, L., Antonângelo, L., dos Santos, A., & Ponce, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.705636 · Cited by 16
“…two specific populations: children undergoing cardiac surgery and patients receiving kidney transplantation; however, it did not perform as well in critically ill children or adults and in adults undergoing cardiac surgery (Levey et al., 2009; Schiffl and Lang, 2012; Liu et al., 2013; Ronco, 2014).”
BackgroundGarreau, R., Falquet, B., Mioux, L., Bourguignon, L., Ferry, T., Tod, M. M., Wallet, F., Friggeri, A., Richard, J., & Goutelle, S. (2021) · Antibiotics · doi:10.3390/antibiotics10101228 · Cited by 16
“In both populations, TDM was performed as part of routine patient care, in accordance with guidelines [37].”
MethodBavaro, D. F., Belati, A., Bussini, L., Cento, V., Diella, L., Gatti, M., Saracino, A., Pea, F., Viale, P., & Bartoletti, M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2299377 · Cited by 19
“These concentrations are achieved at VAN doses of 15–20 mg/kg (based on actual body weight) administered every 8–12 hours as an intermittent infusion for most patients with normal renal function [74].”
BackgroundOsteomyelitis: An Update for Hospitalists
Howell, W. R., & Goulston, C. (2011) · Hospital Practice · doi:10.3810/hp.2011.02.386 · Cited by 16
“Therapeutic monitoring to improve optimal serum concentrations when using vancomycin is recommended by many authorities, although evidence to support this is limited.(60) There is also increasing concern that vancomycin may have slower bacterial killing than was previously recognized.”
BackgroundWu, Y., Kang, J., & Wang, Q. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2803-9 · Cited by 16
Allometric versus consensus guideline dosing in achieving target vancomycin trough concentrations
Brown, M. L., Hutchison, A. M., McAtee, A. M., Gaillard, P. R., & Childress, D. T. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160260 · Cited by 16
Application of vancomycin in patients with augmented renal clearance
Chu, Y., Luo, Y., Jiang, M., & Zhou, B. (2019) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2018-001781 · Cited by 16
Helset, E., Nordøy, I., Sporsem, H., Bakke, V. D., Bugge, J. F., Gammelsrud, K. W., Zucknick, M., & Lippe, E. V. D. (2020) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.13658 · Cited by 20
“Vancomycin therapy initiation, ICU day 8 (3-16) 0”
BackgroundZhang, B., Skelly, J. D., Braun, B. M., Ayers, D. C., & Song, J. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00600 · Cited by 17
Pongchaidecha, M., Changpradub, D., Bannalung, K., Seejuntra, K., Thongmee, S., Unnual, A., & Santimaleeworagun, W. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.4.573 · Cited by 17
“The previous guideline suggested trough concentration for vancomycin dosing adjustment [9].”
BackgroundFiore, M., Peluso, L., Taccone, F. S., & Hites, M. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1902985 · Cited by 18
“The widely accepted PD target is an AUC0-24/MIC >400 [70,71].”
Fransson, M., Helldén, A., Balkhed, Å. Ö., Dernroth, D. N., Ha, M., Haglund, M., Milos, P., Hanberger, H., & Kågedal, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.728075 · Cited by 16
D’Amico, H., Wallace, K. L., Burgess, D. R., Burgess, D. S., Cotner, S. E., Mynatt, R. P., Li, N., Stromberg, A. J., & VanHoose, J. D. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00886-21 · Cited by 16
“marker for 24-h area under the curve (AUC24) to MIC ratio of $400 mg hr/liter for Staphylococcus aureus (8).”
BackgroundShayesteh, O. H., Mahjub, R., Ranjbar, A., Derakhshandeh, K., & Jamshidi, M. (2021) · Microchimica Acta · doi:10.1007/s00604-021-05003-9 · Cited by 17
Nailor, M. D., & Sobel, J. D. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.03.011 · Cited by 20
Pediatric Assessment of Vancomycin Empiric Dosing (PAVED): a Retrospective Review
Rainkie, D. C., Ensom, M. H. H., & Carr, R. R. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0122-8 · Cited by 16
“Current guidelines from the Infectious Disease Society of America (IDSA) for the therapeutic monitoring of vancomycin recommend that trough concentrations be drawn before the fourth dose (at steady-state conditions) in adult patients who are at high risk for nephrotoxicity, have unstable renal function, or are likely…”
BackgroundInfluentialStockmann, C. R., Roberts, J. K., Tian, Y., Constance, J. E., Knibbe, C. A. J., Spigarelli, M. G., & Sherwin, C. M. T. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.966081 · Cited by 16
“To rapidly reach steady state, a loading dose of 25 mg/kg may be considered [75].”
BackgroundMethodInfluentialVancomycin Dosing and Pharmacokinetics in Postoperative Pediatric Cardiothoracic Surgery Patients
Benefield, E. C., Hagemann, T. M., Allen, H. C., Farmer, K., Burton, M. E., Chávez‐Bueno, S., & Johnson, P. N. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.1.66 · Cited by 16
Ortwine, J. K., Pogue, J. M., & Faris, J. J. (2014) · Journal of Burn Care & Research · doi:10.1097/bcr.0000000000000147 · Cited by 16
Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies
Durand, C. R., Bylo, M., Howard, B. G., & Belliveau, P. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017750084 · Cited by 16
“Troughs should be at least 10 μg/mL, with targets of 15 to 20 μg/mL for pathogens with minimum inhibitory concentrations ≥1 μg/mL and for patients with complicated infections.(1) These guidelines suggest dosing and monitoring of vancomycin therapy in obese patients in a fashion similar to nonobese patients.”
BackgroundMethodInfluentialIs there still a role for vancomycin in skin and soft-tissue infections?
Savoldi, A., Azzini, A. M., Baur, D., & Tacconelli, E. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000432 · Cited by 17
Peyko, V., & Friedman-Jakubovics, M. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160760 · Cited by 16
Prevention and Treatment of Multidrug-Resistant Organisms in End-Stage Renal Disease
Midturi, J. K., & Ranganath, S. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2018.09.003 · Cited by 18
Marella, P., Roberts, J. A., Hay, K. E., & Shekar, K. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01179-20 · Cited by 16
Snydman, D. R. (2012) · Journal of Hospital Medicine · doi:10.1002/jhm.980 · Cited by 17
“Guidelines from the American Society of HealthSystem Pharmacists, IDSA, and Society of Infectious Diseases Pharmacists recommend vancomycin serum trough concentrations of 15-20 mg/L for patients with bacteremia due to MRSA.91 These levels are recommended to improve penetration, increase the probability of obtaining op…”
BackgroundNosocomial Bacterial Meningitis
Nesseler, N., Launey, Y., & Seguin, P. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1001713 · Cited by 16
Treatment of MRSA infections in India: Clinical insights from a Delphi analysis
Singhal, T., Rodrigues, C. S., Soman, R. N., Wattal, C., Swaminathan, S., Nambi, S., Talwar, D., Singh, R. K., & Todi, S. K. (2021) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2021.11.005 · Cited by 19
Chamorro-García, A., Parolo, C., Ortega, G., Idili, A., Green, J., Ricci, F., & Plaxco, K. W. (2022) · Chemical Science · doi:10.1039/d2sc03901j · Cited by 15
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.